Patients with different forms of multiple sclerosis were treated with a vaccine consisting of myelin-reactive T cells. It was found that after this treatment, lymphocytes from patients acquired the capacity to generate antiidiotypic proliferative response directed towards myelin-reactive T cells. The serum concentration of IFN-γ decreased about 2-fold 1.5–2.0 years after the start of vaccine therapy, whereas the concentration of IL-4 increased 2–3 fold. Myelin-reactive proliferative activity of peripheral blood mononuclear cells also decreased. The results of the 2-year follow-up study revealed no side effect of T-cell vaccination in patients with cerebrospinal form of multiple sclerosis and demonstrated its possible clinical efficiency in the treatment of this disease at early stages.
Similar content being viewed by others
References
I. P. Ivanova, V. I. Seledtsov, N. V. Banul, et al., Med. Immunol., 7, No. 1, 27–32 (2005).
J. Correale, B. Lund, M. McMillan, et al., J. Neuroimmunol., 107, No. 2, 130–139 (2000).
G. E. Deibler, R. E. Martenson, and M. W. Kies, Prep. Biochem., No 2, 139–165 (1972).
N. Hellings, J. Raus, and P. Stinissen, Autoimm. Rev., 3, 267–275 (2004).
G. Hermans, R. Medaer, J. Raus, and P. Stinissen, J. Neuroimmunol., 102, No. 1, 79–84 (2000).
P. Stinissen, J. Zhang, R. Medaer, et al., J. Neurosci. Res., 45, 500–511 (1996).
P. Stinissen and J. Raus, Acta Neurol. Belg., 99, 65–69 (1999).
S. C. Strom, Methods Enzymol., 82, Pt. 2, 554–555 (1982).
A. A. Vandenbark, E. Morgan, R. Bartholomew, et al., Neurochem. Res., 26, 713–730 (2001).
Y. C. Q. Zang, J. Hong, M. V. Tejada-Simon, et al., Eur. J. Immunol., 30, 908–913 (2000).
J. Zhang, P. Stinissen, R. Medaer, and J. R. Raus, J. Mol. Med., 74, 653–662 (1996).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Kletochnye Tehnologii v Biologii i Medicine, No. 3, pp. 145–150, August, 2008
Rights and permissions
About this article
Cite this article
Ivanova, I.P., Seledtsov, V.I., Seledtsova, G.V. et al. Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis. Bull Exp Biol Med 146, 133–138 (2008). https://doi.org/10.1007/s10517-008-0237-9
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-008-0237-9